Baxter’s Homechoice Claria APD System Receives the US FDA’s 510 (k) Clearance for Kidney Failure

 Baxter’s Homechoice Claria APD System Receives the US FDA’s 510 (k) Clearance for Kidney Failure

Baxter’s Homechoice Claria APD System Receives the US FDA’s 510 (k) Clearance for Kidney Failure

Shots:

  • Baxter has received the FDA’s clearance for its APD system designed for home use, combining it with Sharesource that aims to help patients with kidney disease manage their care remotely
  • The Homechoice Claria system was cleared for both adults and children. Its interface is available in 38 languages and features step-by-step, voice-activated instructions through an app to guide the user through therapy
  • The clearance follows the recent finalization of the ESRD ETC payment model aims to increase the number of new patients with kidney failure who receive home dialysis and organ transplants. Homechoice Claria with Sharesource will be available in the US in the coming weeks

Click here ­to­ read full press release/ article | Ref: Baxter | Image: BusinessWire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post